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D o s s i e r
This paper examines the forms of political 
activism that have emerged around orphan drugs 
from the late 1970s to the contemporary present. 
The ﬁrst paper of the paper will illustrate how 
the problem of developing drugs aimed at 
treating rare diseases was made knowable to 
political authorities in the United States through 
a combination of patient group activism, 
congressional hearings, surveys, academic 
conferences, and media reports. Through the 
formation of an effective coalition, patients’ 
associations were able to aid the passage of 
legislation speciﬁcally concerned with altering 
the economic and regulatory circumstances that 
previously prevented pharmaceutical companies 
from developing treatments targeted at rare 
diseases. In the second section of the paper, I 
will move on discuss how the US Orphan Drug 
Act (1983) has been adopted as a policy model 
in a number of countries such as Singapore, 
Japan, Australia, and most recently, throughout 
european member states. The paper will examine 
the impact that this legislation has had on the 
biotechnology industry, which has beneﬁted 
considerably from the provisions contained 
within orphan drug legislation. Lastly, the 
paper will conclude by examining some of the 
contemporary biopolitical problems that orphan 
drugs pose in terms of the high cost of some 
of these therapies. The emerging contours of 
this problem consists of reconciling providing 
expensive treatments for a small number of 
patients whilst still trying to meet and ﬁnance the 
healthcare needs of the general population. As 
part of this examination, reference will be made 
to the practices and forms of thought (health 
technology assessment or pharmacoeconomics) 
that are used to inform decisions regarding the 
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funding of medical treatments in contemporary 
European health care systems. Through this 
paper, I propose to examine how patient 
activism around orphan drugs has shifted from 
attempting to shape the economic and regulatory 
circumstances that prevented the marketing of 
orphan drugs to attempting to challenge the 
administrative and bureaucratic procedures that 
now prevent patients from having access to 
these therapies.
Origins of the orphan drug problem
The orphan drug problem illustrates how the 
advocacy efforts of patients’ groups can extend 
beyond the scope of their illnesses and may en-
compass economic and regulatory policy (Epstein 
1996; Rabeharisoa 2003).  Orphan drugs refer to 
pharmaceutical or biological therapies intended 
for the treatment of rare diseases. Prior to the 
advocacy efforts of patients’ groups, pharmaceu-
tical companies had little ﬁnancial incentive to 
invest in the research, development or marketing 
of drugs targeted at small patient populations. 
Beginning in the late 1970s, a number of patients’ 
groups in the United States began to question 
the regulatory and economic circumstances that 
prevented the development or marketing of po-
tentially therapeutically important drugs for rare 
diseases such as myoclunus, Tourette’s syndrome, 
or Wilson’s disease. The advocacy efforts of 
patients’ groups primarily concentrated on the 
regulatory procedures at the U.S. Food and Drug 
Administration (FDA), in addition to the failure 
of pharmaceutical companies to invest in the 
development or marketing of orphan drugs.  
Throughout the 1970s, some effort was made on 
the part of regulatory agencies within the U.S. 
bureaucracy to address the orphan drug problem 
through the formation of two inter-governmental 
committees (Asbury 1985). However, these com-
mittees met with limited success due to lack of 
agreement on what constituted orphan drugs and 
limited knowledge of drugs intended for small pa-
tient populations (Asbury 1985). It was not until 
the late 1970s and early 1980s that awareness of 
the orphan drug problem became widespread and 
a signiﬁcant political issue due to the activism of 
a number of patients’ organisations. One group 
that brought the orphan drug problem to the fore-
ground was the National Myoclunus Foundation, 
a myoclunus sufferer named Sharon Dobkin, and 
an academic scientist, Dr. Melvin Van Woert. For 
many years they had tried to ﬁnd a pharmaceutical 
company willing to develop and market a prom-
ising therapy for myoclonus known as L-5HP. 
Based on the lack of interest they encountered 
from the pharmaceutical sector and the state, they 
decided to attempt to inﬂuence policy around the 
orphan drug issue (Van Woert 1983). Towards this 
end, Sharon Dobkin contacted her elected ofﬁcial, 
Representative Elizabeth Holtzman. Based on 
hearing Dobkin’s experience and that of Dr. Van 
Woert in trying to ﬁnd a sponsor for L-5HP, on 
April 23, 1980, Holtzman introduced a Bill in 
Congress proposing the creation of an Ofﬁce of 
Drugs of Limited Commercial Value within the 
US National Institutes of Health (NIH). What is 
signiﬁcant about Holtzman’s Bill in relation to the 
orphan drug problem was that it initiated a series 
of congressional hearings on this topic chaired 
by Henry A. Waxman (United States Congress 
1981). These hearings provided an important 
venue for representatives from patients’ groups 
such as National Myoclunus Foundation, the 
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Tourrette Syndrome Association and the National 
Huntington’s Disease Association to provide tes-
timony. Their testimony helped to raise awareness 
of the plight of persons affected by rare diseases 
and the lack of treatments for their conditions. 
As the Hearings also gave an opportunity for 
representatives from the pharmaceutical industry 
and the FDA to testify, it created an important 
forum for the development of knowledge around 
a previously marginalised problem.
The testimony presented by patients at the Hear-
ings ﬁt into a dominant “drug lag” discourse 
present in the United States from the early 1970s 
to mid-1980s (Daemmrich & Krücken 2000). 
This discourse suggested that stringent FDA 
procedures led to lengthy delays in the marketing 
of new drugs in comparison to other countries, 
causing unwarranted suffering and loss of life to 
American patients. The claims made by patients 
at the Hearings aligned themselves to this dis-
course through the suggestion that the lengthy and 
costly procedures present at the FDA for appro-
ving drugs further discouraged pharmaceutical 
companies from investing in the development 
or marketing of drugs intended for small patient 
populations. Patients’ groups, academic scientists 
and the pharmaceutical industry often pointed 
to the 1962 Kefauver-Harris Amendments to 
the Food and Drug Act as being responsible 
for these regulatory delays. These amendments 
were introduced due to the thalidomide disaster. 
In response to this disaster, the FDA, alongside 
authorities in a number of countries began to 
require greater safety and efﬁcacy data based on 
adequately conducted clinical trials prior to the 
approval of a drug for sale (Asbury 1985; Daem-
mrich & Krücken 2000; Wiktorowicz 2003). 
One of the consequences of these amendments 
was that it increased drug development times 
and costs. Based on the claim that pharmaceuti-
cal companies did not have sufﬁcient economic 
incentives to develop or market drugs targeted 
at small patient populations, patients’ groups 
proposed that a series of grants or subsidies were 
required to stimulate industry to develop these 
types of drugs. Patients’ groups further shaped 
their claims about orphan drugs in a language 
appropriate to a Reaganite era. They argued that 
orphan drugs would allow individuals affected 
by rare diseases to exercise independence and 
become economically productive members of 
society, rather than a burden on their families or 
the state. Here, patients’ groups often mobilised 
a discourse that balanced the costs of disability 
and welfare provision in contradistinction to the 
social beneﬁts of “putting people back to work” 
and the costs of drug treatment (see statements 
by Abbey Myers, Jack Klugman and MS Society, 
United States Congress 1981). By extending the 
“drug lag” discourse to incorporate orphan pro-
ducts, proposing potential solutions to the orphan 
drug problem, and by highlighting the difﬁculties 
experienced by persons suffering from rare dis-
eases, patients’ groups were able to articulate the 
necessity of action on the behalf of government 
and industry to resolve this issue. 
The claims made by patients’ groups that the 
pharmaceutical industry was failing to meet the 
therapeutic needs of persons affected by rare 
disorders found support in a survey conducted 
as part of the Congressional hearings (Asbury 
1985). One of the key ﬁndings of this survey 
was that out of a total of 35 drugs that the phar-
maceutical industry claimed it marketed for the 
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treatment of rare diseases, only 10 of these drugs 
had been directly developed by industry without 
the assistance of federal government agencies 
(Asbury 1985). This survey was signiﬁcant in 
that it provided for the ﬁrst time extensive knowl-
edge of the scope of the orphan drug problem 
and demonstrated the failure of the market and 
pharmaceutical industry to meet the therapeutic 
needs of persons affected by rare disorders. 
Aside from the congressional survey, the 
early 1980s witnessed the growing prolifera-
tion of knowledge in relation to the orphan drug 
problem through the organization of a series of 
conferences and the publication of a number of 
books (Brewer 1983; Karch 1982; Scheinberg 
& Walshe 1986; Van Woert & Chung 1985). 
The conferences and the publications related 
to them brought together representatives from 
patients’ groups, industry and academic scien-
tists.  Through this process of dialogue and 
contestation, a general outline emerged about the 
prominent economic and regulatory factors that 
contributed to the orphan drug problem. These 
factors included the rising costs associated with 
bringing a new drug to market, the prospect of 
limited economic returns associated with drugs 
targeted at small patient populations, the unpa-
tentable status of many orphan drugs, in addition 
to the difﬁculties and higher costs associated 
with conducting clinical trials related to rare dis-
eases. The claims of academic scientists played 
an important role in supporting the struggles of 
patients’ organizations. They helped to deﬁne the 
contours of the problem, illustrate the difﬁculties 
they encountered in attempting to develop pro-
mising treatments for rare conditions, and often 
gave moving accounts of the suffering they wit-
nessed in their clinical practices. The conferences 
also served the important function of providing 
an important meeting place for representatives of 
different patients’ organizations. Based on their 
mutual interest in securing the passage of orphan 
drug legislation, the representatives from patients’ 
group present at  a conference in Ann Arbor, 
Michigan on September 27-29, 1982 decided to 
unite their efforts and form a coalition known 
as the National Organisation for Rare Disorders 
(Brewer 1983). The formation of this coalition 
enabled patients’ groups to lobby more effectively 
for the passage of the Orphan Drug Act. 
Throughout the entire process of the negotiation 
of the orphan drug bill, patients’ groups effec-
tively used the media to give voice to their claims. 
Through a fortuitous twist of fate, the testimony 
presented at the Hearings formed the basis of an 
episode of the popular 1980s television series 
Quincy M.D.  Based on reading a Los Angeles 
Times (Maye 1980) account of the testimony pre-
sented by Adam Seligman (a sufferer of Tourette’s 
syndrome who had to resort to smuggling the drug 
Pimozide from Canada to treat his condition) the 
producers of Quincy M.D. created an episode 
around the orphan drug issue (Henkel 1999 ; 
Meyers 1985). This episode aired ﬁve days before 
the second round of Congressional hearings that 
took place in relation to orphan drugs. Based 
on his performance, the star of Quincy M.D., 
Jack Klugman, received an invitation to present 
testimony at the hearings. His testimony drew 
considerable media attention to the orphan drug 
problem and the plight of persons affected by 
rare diseases. On the same day of Klugman’s 
testimony, the Pharmaceutical Manufacturers 
Association of America announced that it was 
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creating a Commission on Drugs for Rare 
Diseases (Cohn 1981). The Quincy M.D. epi-
sode helped to spur action on the orphan drug 
problem from the pharmaceutical industry and 
enabled representatives from patients’ group to 
gain national media attention. Through effective 
use of the media, the personal problems and dif-
ﬁculties experienced by persons affected by rare 
disorders became transformed into a national 
issue. The capability of the Quincy M.D. show to 
capture media attention was put to use again when 
a second episode on orphan drugs was created and 
televised at around the same time that the Orphan 
Drug Bill was having difﬁculty being approved 
in the U.S. Congress and Senate. Patients’ groups 
used this episode to launch a newspaper and a 
telephone campaign to call the White House to 
encourage President Reagan to sign the Orphan 
Drug Bill into Law (Anonymous 1982). President 
Reagan signed the Orphan Drug Bill into law on 
January 3, 1983. 
The Congressional hearings related to the Orphan 
Drug Bill were historically signiﬁcant in ﬁnding 
a resolution to the orphan drug problem. In the 
ﬁrst instance, the testimony provided by patients 
documented their difﬁculties in gaining access 
to treatments and led to the recognition of the 
special needs and difﬁculties faced by persons 
affected by rare diseases. The Hearings further 
noted the failure of the pharmaceutical industry, 
the state, and the medical profession to satisfy the 
needs of this population. Based on the evidence 
presented at the Hearings it legitimised the neces-
sity of governmental intervention to resolve this 
problem. The Hearings made the orphan drug 
problem amenable to governmental thought and 
intervention by deﬁning the scope of this prob-
lem, facilitating the proposition of potential solu-
tions, and delineating the responsibilities of the 
public and private sectors. The advocacy efforts 
of patients’ groups throughout the entire process 
of the negotiation of orphan drug legislation was 
crucial to securing the collaboration of the phar-
maceutical industry and the state in developing 
economic and regulatory incentives to foster the 
development and marketing of drugs intended
for rare diseases. In its ﬁnal form, the American 
Orphan Drug Act uses a range of legal and eco-
nomic incentives to promote the development of 
orphan drugs.  These incentives include 7 years 
of marketing exclusivity for a drug or therapy 
labelled as an orphan product, tax credits for clini-
cal trial related expenses, as well as assistance 
with the drug application process. The legislative 
intention of the Orphan Drug Act is to channel, 
redistribute and modify some of the uncertain-
ties and risks associated with the development 
of drugs aimed at small patient populations. As 
we will see in the following section, the Orphan 
Drug Act has successfully increased the number 
of therapies available to patients affected by rare 
diseases.
Markets, ﬁrms and the Orphan Drug Act 
The struggle of patients’ groups to pass orphan 
drug legislation suggestively illustrates how their 
efforts can have a lasting economic and regulatory 
legacy. As a solution to the failure of markets to 
develop treatments for rare diseases, the legal and 
economic incentives contained within the Orphan 
Drug Act have been successful in shaping the 
conduct of ﬁrms, industry, regulatory agencies in 
directions considered socially and economically 
desirable. By many accounts, the Orphan Drug 
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Act is considered as one of the most successful 
pieces of health related legislation passed in 
the United States (Haffner 2006 ; Pulsinelli 1999 ; 
Tambuyzer 2000). 
In the ﬁrst instance, this legislation has shaped 
the conduct of ﬁrms as can be judged by the 
dramatic increase in the number of therapies 
marketed to treat rare and life threatening condi-
tions. Secondly, as a governmental technology 
for encouraging the development of rare disease 
treatments, the American Orphan Drug Act has 
been adopted as a policy model by other countries 
and regions. Lastly, the impact of the Orphan 
Drug Act in shaping drug development markets 
can be evaluated by the growing numbers of ﬁrms 
that specialise in the development of treatments 
for rare diseases. What is signiﬁcant about the 
provisions contained within the Orphan Drug Act 
is that they have effected a revaluation of rare dis-
eases: previously these illnesses were considered 
to be of limited commercial value, now they are 
considered a potentially proﬁtable market sector.
The Orphan Drug Act (ODA) has had an inﬂu-
ence on the research and investment decisions 
of the drug development industry. By removing 
some of the risks and uncertainties previously 
associated with the development of drugs targeted 
at small patient populations, the ODA has posi-
tively shaped the kinds of illnesses and patient 
populations which private industry decides to 
treat or cure. One measure used to evaluate the 
success of this legislation is the number of orphan 
drug marketed since 1982. In contrast to the 35 
orphan drugs on the market in the 1970s, since the 
passage of orphan drug legislation, 285 of these 
drugs are now marketed (Haffner et al. 2002). 
Commercial interest in these drugs is further 
measured by the number of applications made 
for orphan drug designation – a ﬁgure which 
presently stands at 1917 (Haffner et al. 2002). The 
signiﬁcant growth in the number of orphan drugs 
marketed can be attributed to the growth of the 
biotechnology industry from the 1980s onwards. 
As many rare diseases are genetic in origin, the 
legal and economic incentives contained within 
the Act provide a stimulus to an emergent bio-
technology industry (Haffner et al. 2002; Meyers 
1992; Tambuyzer 2000). 
The ODA has had a signiﬁcant impact on the 
biotechnology industry. Although the ODA was 
designed to provide a range of incentives to the 
pharmaceutical industry, its greatest impact has 
been on the biotechnology industry. The ODA 
is often credited with fomenting the growth and 
development of this industrial sector. For many 
start-up biotechnology companies, orphan pro-
duct designation is often seen as instrumental 
to securing venture capital investment due to 
the prospect of 7 years of marketing exclusivity 
and the tax credits associated with clinical trial 
related expenses. The signiﬁcance of the ODA to 
this nascent industry is best captured in an article 
in Nature Biotechnology which report that “56% 
biotechnology products launched between 1982 
and 2000 were ﬁrst approved for orphan drug 
indications…” (Ashton 2001; see also Haffner 
et al. 2002). The ODA has effectively shaped 
the conduct of particular companies who have 
found a niche in satisfying unmet medical needs 
and corporate bottom lines. The ODA has not 
only shaped the conduct of markets and ﬁrms, 
it has contributed signiﬁcantly to the health of 
populations affected by rare diseases.  
QUADERNI N°68 - HIVER 2008-2009 ORPHAN DRUGS... .19
By acting upon the economic circumstances 
surrounding the development of drugs for small 
patient populations, it is often claimed that the 
ODA has augmented the health of the estimated 
20-25 million Americans affected by rare dis-
eases. It is suggested that 14 million Americans 
have beneﬁted from new treatments for their 
rare illnesses (Haffner et al. 2002). According to 
Marlene Hafner (2003: 374), 85 percent of orphan 
designations are for the treatment of serious or 
life threatening conditions such as rare forms of 
cancer or metabolic disorders. 
What I believe to be of further signiﬁcance is 
how the Act has extended the clinical reach of 
medicine to conditions where no viable treat-
ment option previously existed. Patients’ groups, 
industry and the FDA argue that the success 
of the ODA in promoting the development of 
new treatments and contributing to human well 
being has led to the adoption of this legislation 
in locales outside the United States. 
The American Orphan Drug Act has further 
served as a model for the development of similar 
legislation in Singapore, Japan, Australia and 
most recently, the European Union. As a govern-
mental model, the Orphan Drug Act is valued 
since it combines a programme for the achieve-
ment of public health objectives, in addition to 
promoting innovation in the nationally strategic 
important area of biotechnology. The adoption 
of this legislation in other countries involves 
recognition that the market fails to develop treat-
ments for rare diseases in the absence of state 
intervention. It further involves a re-prioritisation 
of the health needs of persons affected by rare 
disorders. In the case of the European Union, 
patients’ group lobbied hard to get orphan drug 
legislation approved and their efforts received 
assistance from NORD. 
Despite the rather rosy picture I have painted, 
the creation of favourable market conditions for 
the development of rare disease treatments is 
not without a number of problems. The Orphan 
Drug Act was initially developed to encourage 
ﬁrms to develop therapies where there was no 
reasonable prospect of them making a reasonable 
return on their investment, let alone signiﬁcant 
proﬁts. However, some orphan drugs are amongst 
the most expensive in the world. Let me take the 
example of drug developed by Genzyme known 
as Cerezyme. The average annual cost of treating 
a patient with Cerezyme varies from $70,000USD 
to $300,000USD dependent on dosage and body 
weight. Considering that a treatment such as 
Cerezyme is required for the remainder of a 
patient’s life it generates substantial revenues. 
Genzyme is not alone in producing proﬁtable 
orphan drugs : Genentech’s Propotin, Amgen’s 
Epogen, and Novartis’ Gleevec have all managed 
to make it on to the list of the top 100 selling 
drugs. It is important to emphasise that the vast 
majority of orphan drugs have sales in the region 
of $15-20USD million and are not proﬁtable. The 
topic that I would like to move on to discuss is 
how the high cost of a high cost of a small number 
of orphan drugs raises the more serious problem 
of how national health care systems are able to 
pay for these treatments. 
Pharmacoeconomics, orphan drugs and 
contemporary patient activism 
Within the ﬁeld of rare disease activism one of the 
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key sites of struggle that has emerged in recent 
years is around access to medicines. From the mid 
1980s onwards, European and North American 
states became increasingly concerned with redu-
cing their healthcare expenditures in the face of 
an exponential increase in the number of diseases 
that can be treated by either pharmaceutical or 
biological means. The high cost of some orphan 
drugs raises the question for national healthcare 
systems of whether the provision of these drugs 
to a small number of patients affected by rare 
diseases will adversely affect its capacity to meet 
the health needs of the general population. As I 
will endeavour to show, patient group activism 
around orphan drugs has shifted towards attempt-
ing to shape the administrative procedures that 
determine patient access to orphan drugs.
The kinds of struggle that rare disease activists 
now engage in are concerned with shaping the 
forms of clinical and economic calculation that 
are used to adjudicate the social distribution of 
health care resources amongst the population. 
One form of calculation used to make health 
care decisions is known as pharmacoeconomics. 
Pharmacoeconomics, as a discipline, is concerned 
with developing a rational set of principles to as-
sess healthcare practices so that the most efﬁcient 
use is made of limited healthcare resources. 
Let me give a more practical example of phar-
macoeconomic assessment based from the United 
Kingdom. A group of Primary Care Trusts based 
in the West Midlands had to decide whether to 
provide enzyme replacement therapies for Gau-
cher’s diseases, Fabry’s disease and MPS 1. These 
therapies, with some reservations, are considered 
clinically effective. However, these therapies are 
expensive. After conducting a pharmacoeconomic 
assessment, the authorities in the West Midlands 
decided not to offer these treatments to patients. 
The justiﬁcation provided for this decision used 
the economic concept of opportunity costs to ad-
dress the normative question of how healthcare 
resources should be distributed amongst different 
sectors of the population (Burls et al. 2005). It 
was suggested that when resources are devoted to 
high cost treatments that affect a small percentage 
of the population, the opportunity costs involved 
consist of there being less resources available to 
fund health interventions that offer better value 
for money and have a greater impact upon the 
health of the population (Burls et al. 2005).
Rare disease patients’ group are not entirely 
satisﬁed when these types of decisions are made 
about the only treatments that are available 
for their conditions. Across the European Union 
and North America, patients’ groups are con-
testing pharmacoeconomic assessments made 
in relation to orphan drugs. They are concerned 
with securing a proportion of national healthcare 
budgets for the treatment of rare diseases. The 
struggle for access to orphan drugs takes place 
across a number of terrains and employs a variety 
of tactics. Patient’s organisations successfully 
use the media to mobilise the suffering expe-
rienced by their members for political purposes 
(Stockdale 1999). By highlighting the plight of 
patients, especially children suffering from life 
threatening rare diseases, who are being denied 
medical treatment due to cost considerations 
generate media interest; elicit empathy from the 
public ; and place signiﬁcant pressure on politi-
cal authorities to act immediately to save a life. 
The ﬁeld of health and social policy constitutes 
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another strategic site of struggle. A key argument 
that is mobilised by patients’ groups is that since 
orphan drug legislation is aimed at promoting 
the development of treatments for rare diseases, 
it makes logical sense for the state to provide 
reimbursement for these drugs through the 
national health care system. In Europe, it is sug-
gested that orphan drug legislation embeds the 
principle that persons affected by rare diseases 
have the same right to treatment as individuals 
affected by common conditions. These types of 
arguments extend into the ﬁeld of healthcare 
ﬁnancing: here, it is argued that although some or-
phan drugs are expensive, given their clinical ef-
fectiveness and the small number of patients that 
require them, they have a minimal impact upon 
overall health budgets (Kanavos & Saka 2005).
Conclusion
The orphan drug problem can be thought of as 
having changed the scale and organizational form 
of rare disease patients’ groups. In the process 
of attempting to enact legislation relating to the 
orphan drug problem, it led to the formation of 
a coalition of patients’ groups known as the Na-
tional Organisation for Rare Disorders (NORD). 
This coalition came about through the realisa-
tion that through binding their efforts together, 
patients’ groups could exert a greater inﬂuence 
on government and the pharmaceutical industry, 
rather than by working individually. In the case 
of orphan drugs, the coalition of diverse patients’ 
groups that mobilised around this problem suc-
ceeded in changing the landscape of pharmaceuti-
cal markets by creating a series of incentives for 
companies to sponsor therapies through the FDA 
approval process. In the 1980s, a different coali-
tion of patient activists, those organised around 
AIDS, were able to further affect changes to the 
regulation of pharmaceutical and the conduct 
of clinical trials (Epstein 1996). This model of 
activism has grown in scope, as witnessed by 
the ever-increasing formation and growth of pa-
tients’ organisations and related coalitions since 
the 1980s. In thinking about this in relation to 
contemporary biopolitics, it could be said that 
by changing the scale of their organizational 
efforts, patients’ organizations have managed 
to integrate themselves into the relays of power 
through which matters of health are thought 
about and acted upon. Through their formation 
into coalitions, patients’ organisations have been 
able to assume of number of important functions 
in relation to the government of health.
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This paper examines the forms of political and scien-
tiﬁc activism that have emerged around orphan drugs 
from the late 1970s to the contemporary present. This 
paper documents the role of a number of patient’s 
groups in fostering the passage of the American Or-
phan Drug Act. The paper then moves on to consider 
the extent to which this legislation has encouraged the 
pharmaceutical and biotechnology industry to develop 
treatments for rare diseases. Lastly, the paper examines 
some of the contemporary biopolitical problems which 
orphan drugs pose in terms of the high cost of a number 
of these types of therapies which limits patient access 
to orphan drugs. 
Drogues orphelines, militantisme médical et soins de 
santé contemporains
Cette contribution analyse les formes de militantisme 
politique et scientiﬁque qui ont émergé autour des 
médicaments orphelins depuis la ﬁn des années 70 
jusqu’à aujourd’hui. Plus particulièrement, cet article 
présente le rôle de différents groupes de patients qui ont 
favorisé le passage de l’American Orphan Drug Act. 
Ensuite, il discute dans quelle mesure la législation a 
encouragé l’industrie pharmaceutique et biotechnolo-
gique à développer des traitements pour les maladies 
rares. Enﬁn, il analyse quelques unes des questions 
biopolitiques contemporaines posées par les drogues 
orphelines, notamment le problème du coût élevé de 
ces formes de thérapies qui limite l’accès du patient 
aux drogues orphelines. 
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